Floatz logo

Voriconazole

Type 2 Diabetes

OrsoBio, IncSmall moleculePhase 1Active
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
73/ 100

Competitive context

55 Active assets in the Type 2 Diabetes cohort.

Asset / SponsorPhaseRating
Liraglutide
RenJi Hospital
Phase 4BBB
Semaglutide
Shanghai Jiao Tong University School of Medicine
Phase 4BBB
Pioglitazone
Seoul National University Bundang Hospital
Phase 4BBB
Empagliflozin
Post Graduate Institute of Medical Education and Research, Chandigarh
Phase 4BBB
Sitagliptin
Brigham and Women's Hospital
Phase 4BB

View all 50 →

Same molecule, other indications

Voriconazole is also rated in:

infectious diseaseDormant
BB
Indicative ·
66 / 100
View asset →
fungal infectious diseaseDormant
B
Indicative ·
63 / 100
View asset →
acute myeloid leukemiaDormant
B
Indicative ·
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →